ALK and non-small cell lung carcinoma: In particular, entrectinib, an orally administered selective inhibitor of ROS1/NTRK/ALK, was demonstrated to be more potent compared to crizotinib and was designed to penetrate the blood–brain barrier, which is of vital clinical importance as the central nervous system (CNS) is the first and sole site of progression in almost half of patients with ROS1 fusion‐positive NSCLC who are treated with crizotinib [25, 26].